Back to Cell Types

DAN-GHomo sapiens (Human)Cancer cell line

Also known as: DAN, DANG, DanG, Dan-G

🤖 AI SummaryBased on 10 publications

Quick Overview

DAN-G is a human cell line used in cancer research, with known genomic and metabolic characteristics.

Detailed Summary

DAN-G is a human cell line derived from pancreatic cancer, characterized by specific genomic alterations and metabolic profiles. It has been utilized in studies focusing on gene copy number variations, metabolic subtypes, and drug sensitivity. Research on DAN-G has contributed to understanding the molecular mechanisms of pancreatic cancer, including the identification of amplified regions and their implications in tumor progression. Additionally, DAN-G has been involved in studies examining the relationship between gene expression and drug response, providing insights into potential therapeutic targets.

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0243
Species	Homo sapiens (Human)
Tissue Source	Pancreas[UBERON:UBERON_0001264]

Donor Information

Age	68
Age Category	Adult
Sex	Female

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	DSMZ
Source ID	ACH-000243_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.972_993+16del38	Homozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly12Val (c.35G>T)	Heterozygous	Acquired	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

13

D12S391

17,20

D13S317

8

D16S539

8,11

D18S51

16

D19S433

13,14

D1S1656

12,17

D21S11

29,31.2

D2S1338

17,18

D3S1358

16

D5S818

12,13

D6S1043

12

D7S820

10,13

D8S1179

10,11

FGA

20

Penta D

9,13

Penta E

7

TH01

9.3

TPOX

10

vWA

16,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Marten A.

World J. Gastroenterol. 11:1521-1528(2005).

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Oncogene 24:1794-1801(2005).

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Veltman J.A., van Kessel A.G., Hoglund M.

Cancer Res. 64:3052-3059(2004).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.

Cha S., Calabresi P.

Cancer Res. 44:1852-1856(1984).

Web Resources